Everest Medicines Announces Positive Results In Preliminary Analysis Of Phase 1B/2A Clinical Trial Of EVER001, A Novel BTK Inhibitor For The Treatment Of Primary Membranous Nephropathy
Everest Medicines Announces Positive Results In Preliminary Analysis Of Phase 1B/2A Clinical Trial Of EVER001, A Novel BTK Inhibitor For The Treatment Of Primary Membranous Nephropathy . (MENAFN - PR Newswire) 
  
  
 
 
 
 
 
   
  Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108953621/Everest-Medicines-Announces-Positive-Results-In-Preliminary-Analysis-Of-Phase-1B2A-Clinical-Trial-Of-EVER001-A-Novel-BTK-Inhibitor-For-The-Treatment-Of-Primary-Membranous-Nephropathy
2024-12-03
rss
(MENAFN - PR Newswire) 
  
  
 
 
 
 
 
   
  Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) ...
Everest Medicines Announces Positive Results In Preliminary Analysis Of Phase 1B/2A Clinical Trial Of EVER001, A Novel BTK Inhibitor For The Treatment Of Primary Membranous Nephropathy